Non-secretory multiple myeloma: Diagnosis and management

被引:13
作者
Charlinski, Grzegorz [1 ,2 ]
Jurczyszyn, Artur [3 ]
机构
[1] Univ Warmia & Mazury, Dept Internal Med, Olsztyn, Poland
[2] Minist Interior & Adm Hosp, Dept Hematol, Warmian Masurian Canc Ctr, Olsztyn, Poland
[3] Jagiellonian Univ Coll Med, Fac Med, Plasma Cell Dyscrasias Ctr, Dept Hematol, Krakow, Poland
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2022年 / 31卷 / 01期
关键词
diagnosis; management; non-secretory multiple myeloma; IMAGING TECHNIQUES; TRANSPLANTATION; DEXAMETHASONE; LENALIDOMIDE; BORTEZOMIB; CRITERIA; OUTCOMES; DISEASE; CHAIN; AGE;
D O I
10.17219/acem/141455
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Multiple myeloma (MM) is one of the most commonly diagnosed blood cancers. One criterion for the diagnosis of MM is serum and/or urine monoclonal protein produced by clonal plasmocytes. However, about 1-2% of MM cases do not have monoclonal protein. If other diagnostic criteria are present, the possibility of a di-agnosis of non-secretory MM should be considered. As the different types of non-secretory MM depend on the underlying cause, the current definition is considered insufficient. Currently, both the diagnosis and treatment of non-secretory MM are the same as those of secretory MM. Due to the rarity of non-secretory MM, most findings are from retrospective studies on small groups of patients and case reports. The method of monitoring the effectiveness of MM treatment remains a problem, as it is usually based on the assessment of the percentage of clonal plasma cells in the bone marrow and imaging studies.
引用
收藏
页码:95 / 100
页数:6
相关论文
共 50 条
[41]   Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management [J].
Gao, Yi ;
Zhou, Di ;
Bai, Xue ;
Wang, Yunjie ;
Wang, Chenchen ;
Bi, Lintao .
FRONTIERS IN PHARMACOLOGY, 2025, 16
[42]   Management of induction failures in newly diagnosed transplant-eligible multiple myeloma [J].
Gertz, Morie A. .
LEUKEMIA & LYMPHOMA, 2020, 61 (01) :1-3
[43]   Daratumumab for multiple myeloma [J].
Croizier, Carolyne ;
Bailly, Sebastien .
BULLETIN DU CANCER, 2018, 105 (11) :985-991
[44]   Cure for multiple myeloma? [J].
Podar, Klaus .
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2025, 18 (02) :108-115
[45]   Panobinostat for the management of multiple myeloma [J].
Sivaraj, Dharshan ;
Green, Michael M. ;
Gasparetto, Cristina .
FUTURE ONCOLOGY, 2017, 13 (06) :477-488
[46]   Updates to the Management of Multiple Myeloma [J].
Callander, Natalie S. ;
Kumar, Shaji K. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
[47]   Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study [J].
McCurdy, Arleigh ;
Seow, Hsien ;
Pond, Gregory P. ;
Gayowsky, Anastasia ;
Chakraborty, Rajshekhar ;
Visram, Alissa ;
Kaedbey, Rayan ;
D'Souza, Anita ;
Mohyuddin, Ghulam Rehman ;
Wildes, Tanya M. ;
Fonseca, Rafael ;
Mian, Hira .
HAEMATOLOGICA, 2023, 108 (12) :3384-3391
[48]   Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study [J].
McCurdy, Arleigh ;
Seow, Hsien ;
Pond, Gregory P. ;
Gayowsky, Anastasia ;
Chakraborty, Rajshekhar ;
Visram, Alissa ;
Kaedbey, Rayan ;
D'Souza, Anita ;
Mohyuddin, Ghulam Rehman ;
Wildes, Tanya M. ;
Fonseca, Rafael ;
Mian, Hira .
REVISTA CHILENA DE LITERATURA, 2023, (108) :3384-3391
[49]   Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma [J].
Touzeau, Cyrille ;
Antier, Chloe ;
Moreau, Philippe .
FUTURE ONCOLOGY, 2021, 17 (09) :993-998
[50]   Management of Multiple Myeloma: A Review for General Practitioners in Oncology [J].
Monteith, Bethany E. ;
Sandhu, Irwindeep ;
Lee, Ann S. .
CURRENT ONCOLOGY, 2023, 30 (05) :4382-4401